Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Korean Journal of Perinatology ; : 158-167, 2013.
Article in Korean | WPRIM | ID: wpr-213469

ABSTRACT

PURPOSE: Ibuprofen is an inhibitor of prostaglandin synthesis and used to close a patent ductus arteriosus (PDA) of preterm infants. This study investigated the association between the response to ibuprofen treatment for PDA and maternal intrauterine inflammation in preterm infants. METHODS: We retrospectively reviewed the medical records of very low birth weight (VLBW) infants diagnosed with PDA, who are admitted immediately after birth in the neonatal intensive care unit at Dongguk University Ilsan Hospital between March 2010 and May 2013. After the first cycle of ibuprofen therapy, infants whose ductus arteriosus was closed and not closed were classified as Responders and Non-responders I, respectively. After the second cycle of ibuprofen therapy, infants with persistent PDA were classified as Non-responders II. We performed multiple logistic regression analysis to determine the most important factor associated with persistent PDA. RESULTS: After the first cycle of ibuprofen therapy, the numbers of Responders and Non-responders I were 40 and 14, respectively. Rate of cesarean section was significantly lower in Non-responders I than that of Responders (P=0.023). In addition, Rate of maternal amnionitis in Non-responder I was significantly higher than that of Responders (P=0.016). By multiple logistic regression analysis, maternal amnionitis was found to be a significant risk factor of the failure of ductus arteriosus closure after the first cycle of ibuprofen treatment (P=0.039). CONCLUSION: The present study shows that maternal amnionitis is an independent risk factor for the treatment failure after the first cycle of ibuprofen therapy in VLBW infants with PDA.


Subject(s)
Female , Humans , Infant , Infant, Newborn , Pregnancy , Amnion , Cesarean Section , Chorioamnionitis , Ductus Arteriosus , Ductus Arteriosus, Patent , Ibuprofen , Infant, Premature , Infant, Very Low Birth Weight , Inflammation , Intensive Care, Neonatal , Logistic Models , Medical Records , Parturition , Retrospective Studies , Risk Factors , Treatment Failure
2.
Journal of Korean Medical Science ; : 164-166, 2013.
Article in English | WPRIM | ID: wpr-86385

ABSTRACT

Hypersensitivity to mosquito bites (HMB) is a rare disease characterized by intense skin reactions such as bulla and necrotic ulcerations at bite sites, accompanied by general symptoms such as high-grade fever and malaise occurred after mosquito bites. It has been suggested that HMB is associated with chronic Epstein-Barr virus (EBV) infection and natural killer (NK) cell leukemia/lymphoma. We describe here a Korean child who presented with 3-yr history of HMB without natural killer cell lymphocytosis. He has been ill for 6 yr with HMB. Close observation and examination for the development of lymphoproliferative status or hematologic malignant disorders is needed.


Subject(s)
Child , Humans , Male , Epstein-Barr Virus Infections/complications , Hypersensitivity/diagnosis , Insect Bites and Stings/diagnosis , Killer Cells, Natural/immunology , Lymphocytosis/complications , Republic of Korea , Skin/pathology
3.
Journal of the Korean Child Neurology Society ; : 112-115, 2012.
Article in Korean | WPRIM | ID: wpr-193622

ABSTRACT

Basilar migraine is a rare type of migraine with complex symptoms including aura such as dysarthria, vertigo, tinnitus, and decreased level of consciousness. A 13-year-old male patient was presented with severe headache and immobility of whole body for 20 minutes after vomiting, dizziness, and dysarthria. Similar episode of headache and unconsciousness after vomiting happened 2 weeks ago prior to the visit. Vital signs were stable and pupils showed positive light reflex. Brain MRI and MRA, EEG, and electrocardiography revealed no abnormality. One day after discharge from hospital, patient revisited emergency room because of similar episode of headache. Preventive medication was started with flunarizine 5 mg per day. However, similar episodes of headache and loss of consciousness repeated three times over the next four months. Topiramate was then added with dose of 100 mg divided into two doses. Since then, the patient has been symptom free over 1 year.


Subject(s)
Adolescent , Humans , Male , Brain , Consciousness , Dizziness , Dysarthria , Electrocardiography , Electroencephalography , Emergencies , Epilepsy , Flunarizine , Fructose , Headache , Light , Migraine Disorders , Migraine with Aura , Paralysis , Pupil , Reflex , Tinnitus , Unconsciousness , Vertigo , Vital Signs , Vomiting
4.
Korean Journal of Pediatric Infectious Diseases ; : 154-162, 2011.
Article in Korean | WPRIM | ID: wpr-75120

ABSTRACT

PURPOSE: The aim of this study was to identify the clinical characteristics of lower respiratory tract infection due to respiratory syncytial virus (RSV) in young children and to provide information for an effective guideline for palivizumab administration in Korea. METHODS: We reviewed medical charts of 167 patients under 3 years of age who were hospitalized in Dongguk University Ilsan Hospital for lower respiratory tract infection between January 2007 and February 2011. Diagnosis of the virus was made based on the multiplex real time polymerase chain reaction. RESULTS: There were 113 patients who were infected by respiratory syncytial virus. 90 patients were term infants and 23 patients were preterm infants. No difference was shown between term and preterm infants except the days of admission which was 9.0+/-6.0 days and 12.6+/-21.0 days respectively. In the preterm group their mean age at the time of admission was 5.21+/-4.9 months and the mean gestational age was 33.1+/-4.3 weeks, and the mean birth weight was 2,152+/-950 g. Only 4 patients were born under 28 weeks gestational age and were candidates for palivizumab administration. CONCLUSION: Most of the patients with severe RSV lower respiratory tract infection were term or near term infants who were not candidates for palivizumab prophylaxis. A nationwide study is needed to make a new risk stratified guideline for RSV prophylaxis for our country.


Subject(s)
Child , Humans , Infant , Infant, Newborn , Antibodies, Monoclonal, Humanized , Birth Weight , Gestational Age , Infant, Premature , Respiratory Syncytial Viruses , Respiratory System , Respiratory Tract Infections , Viruses , Palivizumab
SELECTION OF CITATIONS
SEARCH DETAIL